ZINC05007751
Based on 3 publication(s) in Google Scholar
ZINC05007751 is a potent NIMA-related kinase NEK6 inhibitor with an IC50 of 3.4 μM. ZINC05007751 shows antiproliferative activity against a panel of human cancer cell lines, and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line. ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity was observed against NEK2, NEK7, and NEK9.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.33%
- CAS 番号: 591239-68-8
- 分子式: C18H12N2O3
- 分子量:304.30
-
保管条件:
4°C, protect from light
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 ZINC05007751
More
生物活性
|
NEK6 3.4 μM (IC50) |
ZINC05007751 (6 μM-190 μM; 24 hours) inhibits the growth of MDA-MB-231, PEO1, NCI-H1299 and HCT-15 with IC50 below 100 μM[1].
ZINC05007751 induces perturbation of PEO1 cell cycle[1].
ZINC05007751 (ovarian cancer cells PEO1) shows synergism with Cisplatin, resulting in a significant reduction of Cisplatin IC50 from 7.9 to 0.1 μM, with combination ZINC05007751 (44 μM) + Cisplatin (10 μM) exhibiting the greatest synergistic effect[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231, PEO1, NCI-H1299 and HCT-15 cells
-
Concentration:6 μM-190 μM
-
Incubation Time:24 hours
-
Result:Inhibited the growth of MDA-MB-231, PEO1, NCI-H1299 and HCT-15.
化学情報
-
CAS 番号 591239-68-8
-
性状 Solid
-
分子量 304.30
-
分子式 C18H12N2O3
-
Color Brown to black
-
SMILES
N#CC(C1=O)=C(C)/C(C(N1)=O)=C/C2=CC=C(C3=CC=CC=C3)O2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
KIF26B promotes bladder cancer progression via activating Wnt/β-catenin signaling in a TRAF2-dependent pathway. [Abstract]2025 Apr 19;44(5):115595. PMID: 40253697 -
Antiviral Res
Proteomic and phosphoproteomic analysis of responses to enterovirus A71 infection reveals novel targets for antiviral and viral replication. [Abstract]2023 Dec:220:105761. PMID: 37992763 -
溶剤 & 溶解度
DMSO : 8.33 mg/mL (27.37 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2862 mL | 16.4312 mL | 32.8623 mL | 82.1558 mL |
| 5 mM | 0.6572 mL | 3.2862 mL | 6.5725 mL | 16.4312 mL | |
| 10 mM | 0.3286 mL | 1.6431 mL | 3.2862 mL | 8.2156 mL | |
| 15 mM | 0.2191 mL | 1.0954 mL | 2.1908 mL | 5.4771 mL | |
| 20 mM | 0.1643 mL | 0.8216 mL | 1.6431 mL | 4.1078 mL | |
| 25 mM | 0.1314 mL | 0.6572 mL | 1.3145 mL | 3.2862 mL |
ZINC05007751 関連分類
HY-122639 関連分類
Powered by Bioz